Key result
Anlotinib linked to severe bilateral renal artery stenosis, renovascular hypertension, and AMI.
Why the study?
Anlotinib causes cardiovascular toxicity via endothelial damage, but documentation of concurrent hypertension, bilateral renal artery stenosis, and acute myocardial infarction in a young patient was lacking.
Does anlotinib therapy cause severe cardiovascular toxicity such as renovascular hypertension and coronary artery stenosis in patients with non-small cell lung cancer?
Case Report (n=1)
Does anlotinib therapy cause severe cardiovascular toxicity such as renovascular hypertension and coronary artery stenosis in patients with non-small cell lung cancer?
Anlotinib treatment may accelerate systemic atherosclerosis and induce severe cardiovascular events, necessitating regular cardiovascular monitoring in treated patients.
Anlotinib-associated renovascular toxicity in one case; leaves open causality and need for prospective monitoring data in NSCLC.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2026) conducted a case report in Parotid acinar cell carcinoma with pulmonary metastasis (n=1). Anlotinib was evaluated. Anlotinib treatment in a 35-year-old male with parotid carcinoma induced severe bilateral renal artery stenosis, renovascular hypertension, and acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: